Lumexa Imaging (NASDAQ:LMRI) Releases FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.860-0.900 for the period, compared to the consensus estimate of 0.660. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Stock Up 16.8%

LMRI stock opened at $16.27 on Wednesday. The firm has a market cap of $1.56 billion and a PE ratio of -33.32. Lumexa Imaging has a one year low of $6.45 and a one year high of $19.45. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.44 and a current ratio of 1.44. The firm’s 50 day moving average price is $11.24 and its 200-day moving average price is $11.07.

Lumexa Imaging (NASDAQ:LMRI) last posted its quarterly earnings data on Tuesday, November 10th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.19. The firm had revenue of $271.97 million during the quarter. On average, equities research analysts anticipate that Lumexa Imaging will post 0.25 EPS for the current year.

Wall Street Analyst Weigh In

LMRI has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Lumexa Imaging in a research report on Tuesday, September 22nd. KeyCorp began coverage on shares of Lumexa Imaging in a report on Thursday, September 24th. They issued an “overweight” rating and a $18.00 target price on the stock. Raymond James Financial set a $17.00 price target on shares of Lumexa Imaging in a research report on Monday, September 28th. Barclays lifted their price objective on shares of Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Finally, Wall Street Zen raised shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $16.40.

Lumexa Imaging News Summary

Here are the key news stories impacting Lumexa Imaging this week:

• Positive Sentiment: Lumexa reported EPS of $0.26, beating the $0.07 consensus estimate cited in one report; the company also issued guidance. Article: Lumexa tops Q3 EPS and offers guidance
• Positive Sentiment: Gross profit grew 16.9% year over year to $46.4 million, and operating cash flow rose 193.5% to $34.8 million—signs of improved gross profitability and cash generation. Article: Lumexa Q3 earnings details
• Neutral Sentiment: The earnings call transcript and results release provide additional context, but the supplied reports do not detail the company’s guidance figures or call commentary. Article: Lumexa Q3 2026 earnings call transcript
• Negative Sentiment: Revenue was $272.0 million, up 5% year over year but below the $275.3 million estimate. A separate data analysis reports diluted EPS of $0.07 versus its $0.19 estimate, while operating profit fell 7.3% to $28.1 million. These figures may use a different EPS measure from the $0.26 headline figure. Article: Lumexa Q3 earnings details

Lumexa Imaging Company Profile

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.